Abstract
Minto and Schnider (1) have pointed out that “Rapidly evolving changes in health care economics and consumer expectation make it unlikely that traditional drug development approaches will succeed in the future. A shift away from the narrow focus on rejecting the null hypothesis toward a broader focus on seeking to understand the factors that influence the dose—response relationship together with the development of the next generation of software based on population models (see Section 2.5. for the definition of population models) should permit a more efficient and rational drug development programme.” Their comments are further supported by the fact that the direct cost of drug development has continued to escalate at two and one half times the rate of inflation. The cost of introducing a drug to the market was $802 million in 2000 compared with $237 million in 1987 (2). As an indirect cost, it takes 7–12 yr for a drug to move through development to the final Food and Drug Administration approval (2). Several factors have influenced the escalation in the cost of drug development, including more rigorous approval standards. Regulatory standards are not likely to become less rigorous; therefore, one must look elsewhere to improve the process.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Minto, C. and Schinder, T. (1998) Expanding clinical applications of population pharmacodynamic modeling. Br. J. Clin. Pharmacol. 46, 321–333.
Tufts Center for the Study of Drug Development (2001) Press Release, November 30.
Peck, C. C. (1997) Drug development: Improving the process. Food Drug Law J. 52, 163–167.
Holford, N. H. and Sheiner, L. B. (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6, 429–453.
Dyneka, N. L., Garg, V., and Jusko, W. J. (1993) Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21, 457–478.
Jusko, W. J. and Ko, H. C. (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56, 406–419.
Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., and Ham, J. (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25, 358–371.
Williams, P. J., Lane, J. R., Turkel, C., Capparelli, E. V., Dzewanowska, Z., and Fox, A. (2001) Dichloroacetate: Population pharmacokinetics with a pharmacodynamic sequential link model. J. Clin. Pharmacol. 41, 259–267.
Porchet, H. C., Benowitz, N. L., and Sheiner, L. B. (1988) Pharmacodynamic model of tolerance: Application to nicotine. J. Pharmacol. Exp. Ther. 244, 231–236.
Derendorf, H., Mollman, H., Hochhaus, G., Meibohm, B., and Barth, J. (1997) Clinical PK/PD modeling as a tool in drug development of cortecosteroids. Int. J. Clin. Pharmacol. Ther. 35, 481–488.
Holford, N. H. G. and Peace, K. E. (1992) Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients with tacrine. Proc. Natl. Acad. Sci. USA 89, 11,471–11,475.
Sheiner, L. B., Rosenberg, B., and Marathe, V. (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5, 445–479.
Mandema, J. W., Verotta, D., and Sheiner, L. B. (1992) Building population pharmacokinetic pharmacodynamic models. J. Pharmacokinet. Biopharm. 20, 511–528.
Department of Health and Human Services (1999) Guidance for Industry: Population Phar-macokinetics. US Food and Drug Administration, Rockville, MD.
Sheiner, L. B. and Beal, S. L. (1980) Evaluation of methods for estimating population pharmacokinetic parameters. J. Clin. Pharmacokinet. 9, 635–651.
Steimer, J. L., Mallet, A., and Golmard, J. L. (1984) Alternative approaches to the estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed effects model. Drug Metab. Rev. 15, 265–292.
Egan, T. D., Lemmens, H. J., Fiset, P., Hermann, D. J., Muir, K. T., Stanski, D. R., et al. (1993) The Pharmacokinetics of a new short-acting opioid remifentanil (G187084B) in healthy adult male volunteers. Anesthesiology 79, 881–892.
Kataria, B. K., Ved, S. A., Nicodemus, H. F., Hoy, G. R., Lea, D., Dubois, M. Y., et al. (1994) The Pharmacokinetics of propofol in children using three different analysis approaches. Anesthesiology 80, 104–122.
Sheiner, L. B., Beal, S. L., and Sambol, N. C. (1989) Study designs for dose-ranging. Clin. Pharmacol. Ther. 46, 63–77.
Sheiner, L. B., Hashimoto, Y., and Beal, S. L. (1991) A simulation study comparing designs for dose ranging. Stats Med. 10, 303–321.
Ette, E. I., Williams, P. J., Fadiran, E., Ajayi, F. O., and Onyiah, L. C. (2001) The process of knowledge discovery from large pharmacokinetic data sets. J. Clin. Pharmacol. 41, 25–34.
Ette, E. I. and Ludden, T. M. (1995) Population pharmacokinetic modeling: The importance of informative graphics. Pharmaceut. Res. 12, 1845–1855.
Ette, E. I. (1998) Statistical graphics in pharmacokinetics and pharmacodynamics: A tutorial. Ann. Pharmacother. 32, 818–828.
Rombout, F. (1997) Good pharmacokinetic practice (GPP) and logistics: a continuing challenge, in The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose (Aarons, L., Balant, L. P., Gundert-Remy, U. A., et al., eds.) Office for Official Publications of the European Communities, Luxemborg, pp. 183–193.
Grasela, T. H., Antal, E. J., Fiedler-Kelley, J., et al. (1999) An automated drug concentration screening and quality assurance program for clinical trials. Drug Info. J. 33, 273–279.
Holford, N. H., Kimko, H. C., Monteleone, J. P., and Peck, C. C. (2000) Simulation of Clinical Trials. Annu. Rev. Pharmacol. Toxicol. 40, 209–234.
Reigner, B. G., Williams, P. E. O., Patel, I. H., et al. (1997) An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience with Hoffmann La Roche. Clin. Pharmacokinet. 33, 142–152.
Sheiner, L. B. (1997) Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275–291.
Csajka, C., Buclin, T., Fattinger, K., Brunner, H. R., and Biollaz, J. (2002) Population pharmacokinetic-pharmacodynamic modeling of angiotensin receptor blockade in healthy volunteers. Clin. Pharmacokinet. 41, 137–152.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Williams, P.J., Desai, A., Ette, E. (2003). The Role of Pharmacometrics in Cardiovascular Drug Development. In: Pugsley, M.K. (eds) Cardiac Drug Development Guide. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1385/1-59259-404-2:365
Download citation
DOI: https://doi.org/10.1385/1-59259-404-2:365
Publisher Name: Humana Press
Print ISBN: 978-1-58829-097-7
Online ISBN: 978-1-59259-404-7
eBook Packages: Springer Protocols